Recent Company News

• 04:40 PM ET May 09, 2025
  

  Adagene files $200M mixed shelf; enters into sales agreement for up to $100M of ADSs with Leerink Partners - F-3 ($1.60, 0.00)

• 08:04 AM ET Mar 24, 2025
  

  Adagene reports Q4 EPS ($0.35) vs FactSet ($0.33) [1 est] ($1.69, 0.00)

• 08:02 AM ET Feb 27, 2025
  

  Adagene announces investigator initiated phase 2 trial for Neoadjuvant Muzastotug (ADG126) in colorectal cancer ($1.98, 0.00)

• 06:42 AM ET Jan 31, 2025
  

  Adagene downgraded to equal-weight from overweight at Morgan Stanley ($1.85, 0.00)

• 07:11 AM ET Jan 27, 2025
  

  Adagene announces updated data from phase 1B/2 study of muzastotug in combination with KEYTRUDA (pembrolizumab) in colorectal cancer at ASCO Gastrointestinal Cancers Symposium ($1.93, 0.00)

• 02:03 PM ET Nov 15, 2024
  

  Adagene downgraded to hold from buy at Jefferies (timing uncertain) ($2.25, -0.07)

• 10:05 AM ET Nov 07, 2024
  

  Adagene presents two posters with new insights on increased therapeutic index for masked anti-ctla-4 SAFEbody ADG126 and data reinforcing clinical safety and efficacy for ADG126 ($3.05, 0.00)

• 09:19 AM ET Sep 16, 2024
  

  StreetAccount Summary - US Pre-market trading update

• 08:31 AM ET Sep 16, 2024
  

  StreetAccount Summary - US Pre-market trading

• 03:19 AM ET Sep 16, 2024
  

  Adagene presents results at ESMO for Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) in Combination with (Pembrolizumab) in MSS CRC ($3.49, 0.00)